CompletedNCT01959594

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Medication studyAges 18–55United StatesSchizophrenia

The study in practice

Understand this study

This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Study clarity

Study start dateNovember 2013

Recruitment status: Completed
Enrollment listed in the registry: 40
Sponsor: Pfizer
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: United States
Age range: From 18 Years to 55 Years
Official registry ID: NCT01959594
Official title: Show the full official title
Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of PF-06412562 In Healthy Subjects

Completed

New Haven

FAQ

Who is behind this study?

The study sponsor is Pfizer.

Did this study involve medication?

Yes. The study involved medication, including 3 mg PF-06412562, 10 mg PF-06412562, 25 mg PF-06412562 and PF-06412562 TBD mg.

Who was this study for?

This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.